Novo Nordisk’s SUSTAIN 7 trial results, announced on Wednesday, showed that treating people with type 2 diabetes with once-weekly semaglutide reduced HbA1c and body weight compared to treatment with dulaglutide.
The trial tested the 0.5 mg semaglutide compared with 0.75 dulaglutide, and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin.
Mads Krogsgaard Thomsen, executive vice president and CEO of Novo Nordisk, said: “The superior glucose control and weight loss achieved with semaglutide compared to dulaglutide in this trial reinforces the unprecedented results observed in the entire SUSTAIN programme. We are excited about the potential of semaglutide to set a new standard for treatment of type 2 diabetes”.